Role of dietary supplements in supporting the body in Parkinson’s disease has been identified

Omega-3 fatty acids show some potential in protecting brain cells. A number of clinical trials have recorded a reduction in markers of inflammation and an improvement in antioxidant protection in patients who took these supplements. In some cases, there was an improvement in the Unified Parkinson’s Disease Rating Scale (UPDRS). However, the results remain inconsistent, as most of the successful tests used Omega-3 in combination with vitamin E or other nutrients, making it difficult to assess its independent effect.

Special attention is paid to nicotinamide riboside (a form of vitamin B3). This substance is essential for maintaining the function of mitochondria, the structures responsible for energy production in cells. Clinical evidence suggests that high doses of nicotinamide riboside may improve motor performance, but definitive evidence of its ability to slow down the progression of the disease is still lacking. The effectiveness of the supplement largely depends on the dosage, with studies using higher concentrations showing more promising results.

Vitamin D has been shown to affect cognitive function and inflammation levels, but its role in modifying Parkinson’s disease remains controversial. Research shows variable results, which may depend on the body mass index of patients, the initial dosage and the duration of intake. Vitamin E, which has antioxidant properties, did not show a significant effect on slowing down degenerative processes in isolation. In modern practice, it is more often considered as an auxiliary component in combination with omega-3 fatty acids.

Substances such as creatine and coenzyme Q10, which were previously considered highly promising, have not been confirmed in large long-term trials. Coenzyme Q10 has been officially classified by leading clinical organizations as a substance that cannot slow down the progression of Parkinson’s disease. A similar situation is observed with curcumin: at the moment, there is only one small pilot study in humans, which did not reveal any significant clinical improvements.

The relationship between the state of the intestines and brain health is one of the most dynamically developing areas. Many patients experience digestive disorders years before the appearance of problems with motility, which indicates the intestines as a possible source of pathological processes. People with Parkinson’s disease often have a deficiency of beneficial bacteria that produce short-chain fatty acids.

The use of probiotics, especially multi-strain formulations, has shown the ability to reduce inflammation and symptom severity. Preliminary evidence suggests that probiotics and prebiotics may strengthen the intestinal barrier and reduce oxidative stress, but the evidence base remains limited and requires further research.